If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
28.50    0.00 (0.00%)
Bid:
28.00
Ask:
29.00
Spread: 1.00 (3.571%)
Market Cap: £51.54m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Fuel cell catalyst scale-up agreement

16 Jun 2010 07:00

RNS Number : 6788N
Ilika plc
16 June 2010
 



Ilika plc

 

("Ilika" or the "Company")

 

 

Fuel cell catalyst scale-up agreement

 

 

Ilika and ITRI to scale up and commercialise next generation fuel cell catalysts

 

 

Ilika plc (AIM:IKA), the advanced cleantech materials discovery company, has signed an agreement with Taiwan's premier not-for-profit R&D organisation, the Industrial Technology Research Institute ("ITRI"), to scale-up and commercialise jointly the next generation fuel cell catalysts. The Company believes this agreement will be a vital component of the energy industry's efforts to develop consumer-friendly fuel cell technology.

 

Since initially developing and patenting a lower cost, platinum-free fuel cell catalyst in 2006, Ilika has undertaken further development of the compound and is now confident that it offers cost and availability benefits relative to competing technology.

 

ITRI possesses state-of-the-art integrated abilities in fuel cell technology, including material and device development, manufacturing, application and evaluation, and has agreed to enter into a non-exclusive collaboration to scale-up Ilika's catalyst materials.

 

Under this agreement the parties aim to have samples available to potential customers in approximately 18 months. ITRI will meet the cost of this scale-up work. Thereafter catalyst material should be available for large scale supply during the following 12 months.

 

The parties have also agreed to co-operate in the commercialisation and marketing of the new catalyst, taking full advantage of their global network of potential users.

 

Ilika's Chief Executive, Graeme Purdy, said, "This agreement is a great example of how Ilika develops innovative materials that solve complex industrial challenges together with our partners and shares in the commercial upside that these technological advances make possible.

 

ITRI is a world leader with renowned capability in the field of fuel cell catalysts. We are very pleased it has agreed to enter into this agreement."

 

The global market for fuel cells is growing rapidly, with sales in Europe alone expected to grow to €3.6 billion by 2016. Catalysts make up about 40% of the cost of a typical fuel cell.

 

Dr. Jonq Ming Liu, Vice president and General Director Of Material and Chemical Research Labs, ITRI, concluded, "ITRI hopes to establish more opportunities for international cooperation and technology transfer, and we are delighted to have this opportunity to work with Ilika."

 

 

- Ends -

 

 

For more information contact:

 

Ilika plc

Graeme Purdy, Chief Executive

Steve Boydell, Finance Director

+44 (0) 23 80111400

 

Nomura Code Securities Limited

Phil Walker / Christopher Golden

+44 (0) 20 7776 1200

Pelham Bell Pottinger

Archie Berens/ Olly Scott / Francesca Tuckett

+44 (0) 20 7861 3232

 

 

 

About Ilika

 

Ilika (AIM: IKA) is an advanced materials company which accelerates the discovery of new and patentable materials using its unique high throughput technologies (''HTT'') process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.

 

Traditionally, materials development has been a slow and arduous task, with manual, sequential methods used to make samples of material that are then tested for suitability. On average, it takes between 7 and 10 years to move from an initial discovery through to the first commercial prototype. Experiments carried out by the Company can be executed 10 to 100 times faster than using traditional techniques.

 

The Company focuses on three principal sectors and has a number of active development programmes addressing markets within each sector:

 

Energy - developing innovative new materials for Lithium-ion batteries for vehicles for Toyota; developing high capacity hydrogen storage materials with Shell Hydrogen and Johnson Matthey through joint development programmes; developing cheaper alternatives to Platinum electrodes for use in fuel cells through a grant-funded project with the Carbon Trust; developing new materials for use in fuel cells for the transport sector for a major vehicle manufacturer; and carrying out in-house research on film photovoltaic solar cells.

 

Electronics - developing lead-free piezoelectric materials through a joint development programme with CeramTec; and developing phase change memory materials for high capacity memory.

 

Biomedical - developing polymers to enable the filtering of somatic stem cells from blood with a major global supplier of filters; it has been selling its Cryoskin and Myskin products for the treatment of burns and wounds in the UK through a specialist distributor and intends to commence clinical trials of its corneal bandage candidate.

 

The Group's commercialisation strategy is to enter into joint development or licensing agreements with large multinational companies which are seeking to commercialise products developed using the intellectual property created through jointly-funded programmes. Current commercialisation partners include large multinational companies such as Toyota, Shell, Johnson Matthey and CeramTec. The Company generates revenues from three sources: licensing and milestone payments from joint development programmes; fee for service from contract research projects; and from sales of Cryoskin and Myskin.

 

www.ilika.com

 

About ITRI

 

The Industrial Technology Research Institute (ITRI) is a not-for-profit R&D organization engaging in applied research and technical services. Founded in 1973, ITRI has played a vital role in transforming Taiwan's economy from a labor-intensive industry to a high-tech industry. Numerous well-known high-tech companies in Taiwan, such as leaders in the semiconductor industry TSMC and UMC, can trace their origins to ITRI.

 

Innovative Research

ITRI is a multidisciplinary research center, with six core laboratories, five focus centers, five linkage centers, several leading labs and various business development units. The six fields ITRI focuses on include Information and Communication; Electronics and Optoelectronics; Material, Chemical and Nanotechnologies; Biomedical Technologies; Advanced Manufacturing and Systems; and Energy and Environment. ITRI has aggressively researched and developed countless next-generation technologies, including WIMAX wireless broadband, solar cells, RFID, light electric vehicles, flexible displays, 3-D ICs and telecare technologies. In addition, ITRI's Flexible Electronics Pilot Lab and Nanotechnology Lab provide international-level research platforms where R&D can be conducted jointly with partners. ITRI has also seen significant growth in intellectual property business and new ventures in recent years and is devoted to creating a model that would make Taiwan manufacturing even more competitive in the international arena.

Fostering Entrepreneurship and CEO Leadership

ITRI employs 5,800personnel, including 1,112 who hold Ph.D.s and 3,206with master's degrees, resulting in an average of five patents produced every day. By disseminating both technology and talent, ITRI has led the technology industry into the 21st century and has cultivated 70 CEOs in the local high-tech industry. In addition to its headquarters in Taiwan, ITRI has branch offices in the California Silicon Valley, Tokyo, Berlin and Moscow.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDLIUBBGGU
Date   Source Headline
7th Jul 20265:51 pmRNSResult of Retail Offer
3rd Jul 20267:05 amRNSRetail Offer for up to £0.5 million
3rd Jul 20267:00 amRNSResult of Placing & Director Subscription
2nd Jul 20265:08 pmRNSProposed Capital Raising to raise £5.0 million
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.